Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science spotlight: Biotechs discover new checkpoint target, and more

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst
May 4, 2024 1:50 AM UTC

Shanghai Xunbaihui Biotechnology Co. Ltd. and GV20 Therapeutics LLC identified an immunoglobulin protein as an immune checkpoint expressed on tumor cells that suppresses NK cell cytotoxicity.

Over 65% of all tumors are antigen-presentation-deficient because of loss of HLA-I. Normally, HLA-I acts as a marker of “self,” and cells that lack HLA-I, for example due to viral infection, are killed by NK cells. Somehow, tumor cells avoid this fate...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Arcus Biosciences Inc.

Gv20 Therapeutics LLC

Ioncologi Inc.

RiboX Therapeutics Ltd.

University of Florida